DENVER, Sept. 23, 2022 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share…


Previous articleClearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
Next articleClearmind Announces Notice of Proposed Stock Consolidation